242 related articles for article (PubMed ID: 31553906)
1. Smad7 Controls Immunoregulatory PDL2/1-PD1 Signaling in Intestinal Inflammation and Autoimmunity.
Garo LP; Ajay AK; Fujiwara M; Beynon V; Kuhn C; Gabriely G; Sadhukan S; Raheja R; Rubino S; Weiner HL; Murugaiyan G
Cell Rep; 2019 Sep; 28(13):3353-3366.e5. PubMed ID: 31553906
[TBL] [Abstract][Full Text] [Related]
2. Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression.
Fantini MC; Rizzo A; Fina D; Caruso R; Sarra M; Stolfi C; Becker C; Macdonald TT; Pallone F; Neurath MF; Monteleone G
Gastroenterology; 2009 Apr; 136(4):1308-16, e1-3. PubMed ID: 19192480
[TBL] [Abstract][Full Text] [Related]
3. Leptin antagonist ameliorates chronic colitis in IL-10⁻/⁻ mice.
Singh UP; Singh NP; Guan H; Busbee B; Price RL; Taub DD; Mishra MK; Fayad R; Nagarkatti M; Nagarkatti PS
Immunobiology; 2013 Dec; 218(12):1439-51. PubMed ID: 23726523
[TBL] [Abstract][Full Text] [Related]
4. Smad7 in intestinal CD4
Haupeltshofer S; Leichsenring T; Berg S; Pedreiturria X; Joachim SC; Tischoff I; Otte JM; Bopp T; Fantini MC; Esser C; Willbold D; Gold R; Faissner S; Kleiter I
Proc Natl Acad Sci U S A; 2019 Dec; 116(51):25860-25869. PubMed ID: 31796589
[TBL] [Abstract][Full Text] [Related]
5. TGF-β inhibitor Smad7 regulates dendritic cell-induced autoimmunity.
Lukas D; Yogev N; Kel JM; Regen T; Mufazalov IA; Tang Y; Wanke F; Reizis B; Müller W; Kurschus FC; Prinz M; Kleiter I; Clausen BE; Waisman A
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):E1480-E1489. PubMed ID: 28167776
[TBL] [Abstract][Full Text] [Related]
6. Involvement of Smad7 in Inflammatory Diseases of the Gut and Colon Cancer.
Troncone E; Marafini I; Stolfi C; Monteleone G
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920230
[TBL] [Abstract][Full Text] [Related]
7.
Hang L; Kumar S; Blum AM; Urban JF; Fantini MC; Weinstock JV
J Immunol; 2019 Apr; 202(8):2473-2481. PubMed ID: 30850474
[TBL] [Abstract][Full Text] [Related]
8. Smad7 and its Potential as Therapeutic Target in Inflammatory Bowel Diseases.
Laudisi F; Dinallo V; Di Fusco D; Monteleone G
Curr Drug Metab; 2016; 17(3):303-6. PubMed ID: 26651974
[TBL] [Abstract][Full Text] [Related]
9. Deletion of Smad7 Ameliorates Intestinal Inflammation and Contributes to Fibrosis.
Schuler C; Foti F; Perren L; Mamie C; Weder B; Stokmaier M; de Vallière C; Heuchel R; Ruiz PA; Rogler G; Hausmann M
Inflamm Bowel Dis; 2023 Apr; 29(4):647-660. PubMed ID: 36282601
[TBL] [Abstract][Full Text] [Related]
10. Genetic variants of SMAD2/3/4/7 are associated with susceptibility to ulcerative colitis in a Japanese genetic background.
Yamashita A; Inamine T; Suzuki S; Fukuda S; Unoike M; Kawafuchi Y; Machida H; Isomoto H; Nakao K; Tsukamoto K
Immunol Lett; 2019 Mar; 207():64-72. PubMed ID: 30653987
[TBL] [Abstract][Full Text] [Related]
11. Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFB Signaling and Promote Colitis.
Tang Y; Reissig S; Glasmacher E; Regen T; Wanke F; Nikolaev A; Gerlach K; Popp V; Karram K; Fantini MC; Schattenberg JM; Galle PR; Neurath MF; Weigmann B; Kurschus FC; Hövelmeyer N; Waisman A
Gastroenterology; 2019 Feb; 156(3):692-707.e7. PubMed ID: 30315770
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis.
Boirivant M; Pallone F; Di Giacinto C; Fina D; Monteleone I; Marinaro M; Caruso R; Colantoni A; Palmieri G; Sanchez M; Strober W; MacDonald TT; Monteleone G
Gastroenterology; 2006 Dec; 131(6):1786-98. PubMed ID: 17087939
[TBL] [Abstract][Full Text] [Related]
13. TGF-Beta signaling manipulation as potential therapy for IBD.
Marafini I; Zorzi F; Codazza S; Pallone F; Monteleone G
Curr Drug Targets; 2013 Nov; 14(12):1400-4. PubMed ID: 23489130
[TBL] [Abstract][Full Text] [Related]
14. Expression and function of Smad7 in autoimmune and inflammatory diseases.
Hu Y; He J; He L; Xu B; Wang Q
J Mol Med (Berl); 2021 Sep; 99(9):1209-1220. PubMed ID: 34059951
[TBL] [Abstract][Full Text] [Related]
15. Role of Smad7 in inflammatory bowel diseases.
Monteleone G; Caruso R; Pallone F
World J Gastroenterol; 2012 Oct; 18(40):5664-8. PubMed ID: 23155305
[TBL] [Abstract][Full Text] [Related]
16. The TGF-β/Smad System in IBD Pathogenesis.
Sedda S; Marafini I; Dinallo V; Di Fusco D; Monteleone G
Inflamm Bowel Dis; 2015 Dec; 21(12):2921-5. PubMed ID: 26230862
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of Smad7 With a Specific Antisense Oligonucleotide Attenuates Colitis and Colitis-Driven Colonic Fibrosis in Mice.
Izzo R; Bevivino G; De Simone V; Sedda S; Monteleone I; Marafini I; Di Giovangiulio M; Rizzo A; Franzè E; Colantoni A; Ortenzi A; Monteleone G
Inflamm Bowel Dis; 2018 May; 24(6):1213-1224. PubMed ID: 29668937
[TBL] [Abstract][Full Text] [Related]
18. TGF-beta1 and Smad7 in the regulation of IBD.
Monteleone G; Boirivant M; Pallone F; MacDonald TT
Mucosal Immunol; 2008 Nov; 1 Suppl 1():S50-3. PubMed ID: 19079231
[TBL] [Abstract][Full Text] [Related]
19. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease.
Monteleone G; Kumberova A; Croft NM; McKenzie C; Steer HW; MacDonald TT
J Clin Invest; 2001 Aug; 108(4):601-9. PubMed ID: 11518734
[TBL] [Abstract][Full Text] [Related]
20. Smad7 Knockdown Restores Aryl Hydrocarbon Receptor-mediated Protective Signals in the Gut.
Monteleone I; Marafini I; Zorzi F; Di Fusco D; Dinallo V; Rizzo A; Sileri P; Sica G; Monteleone G
J Crohns Colitis; 2016 Jun; 10(6):670-7. PubMed ID: 26818761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
